nymox_6ka.htm

6-K/A 1 nymox_6ka.htm FORM 6-K/A nymox_6ka.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K/A

(Amendment No. 1)

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of June 2023

Commission File Number: 001-12033

Nymox Pharmaceutical Corporation

(Translation of registrant’s name into English)

Bay & Deveaux Streets, Nassau, The Bahamas

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXPLANATORY NOTE

This Current Report on Form 6-K/A of Nymox Pharmaceutical Corporation (the “Company”) amends the Company’s Current Report on Form 6-K as filed with the Securities and Exchange Commission on June 27, 2023 (the “Original Filing”) to correct a typographical error referring to the Company’s termination of employment of Mr. Christopher R. Riley as the Company’s Chief Financial Officer and of Mr. Randall J. Lanham as the Company’s Chief Operating Officer on June 19, 2023. The correct date of such terminations is June 17, 2023.

Except as described herein, no other changes have been made to the Original Filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 29, 2023

	NYMOX PHARMACEUTICAL CORPORATION

	By:	/s/ Paul Averback
	Name:	Paul Averback
	Title:	President and Chief Executive Officer

SEC Form 6-K/A filed by Nymox Pharmaceutical Corporation (Amendment)